Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07739160) titled 'The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients' on July 28.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
Condition:
Acute Ischemic Stroke
Intervention:
Drug: HRS-4029
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 15, 2026
Target Sample Size: 340
Countries of Recruitment:
China
To know more, visit https://clinicaltrial...